

Remarks

Claims 1-44, 49, 50, 53, 57 and 58 are pending in the application. Examiner has indicated in the advisory action that Claims 1-37, 41-44, 57 and 58 have been allowed. Claims 40 and 53 are objected to as being allowable if rewritten into independent form. Claims 38, 39, 49 and 50 were rejected.

Claims 38 and 39 have been amended to include the limitations of Claim 40 which was objected to as being allowable if rewritten into independent form. Applicant respectfully submits that the incorporation of the Claim 40 limitations into Claims 38 and 39 is the same as an independent form of Claim 40 since it is a multiple dependent claim from Claims 38 and 39. Accordingly, Claim 40 has been cancelled.

Claims 49 and 50 have been amended to include the limitations of Claim 53 which was objected to as being allowable if rewritten into independent form. Applicant respectfully submits that the incorporation of the Claim 50 limitations into Claims 49 and 50 is the same as an independent form of Claim 53 since it is a multiple dependent claim from Claims 49 and 50. Accordingly, Claim 53 has been cancelled.

Applicants respectfully submit that Claims 1-39, 41-44, 49, 50, 57 and 58 are in condition for allowance and request a timely notice of allowance.

Respectfully Submitted:

Date:

January 21, 2005

Arlene K. Musser

Arlene K. Musser
Attorney for Applicants
Registration No. 37,895

Pfizer Inc.
Patent Department, MS: 8260-1611
Eastern Point Road
Groton, Connecticut 06340
(860) 715-0871